According to a recent Reuters article, drug giant Eli Lilly and Co. has requested that the FDA de-authorize its COVID-19 antibody, bamlanivimab. The unique request isn’t linked to safety issues, but in response to new variants of the virus that could be resistant to bamlanivimab when used alone. The government agreed, and stopped distribution of the therapy last month. Facilities that still have supply are being shipped etesevimab to pair with it for a combination treatment that’s more effective.
Eli Lilly Asks FDA to Cancel COVID-19 Antibody Authorization
The pharmaceutical giant will use the antibody as part of a combination treatment for greater efficacy.
Apr 23, 2021
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More